1
|
Rangachari M and Kuchroo VK: Using EAE to
better understand principles of immune function and autoimmune
pathology. J Autoimmun. 45:31–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Leuenberger T, Paterka M, Reuter E, Herz
J, Niesner RA, Radbruch H, Bopp T, Zipp F and Siffrin V: The role
of CD8 (+) T cells and their local interaction with CD4 (+) T cells
in myelin oligodendrocyte glycoprotein 35–55-induced experimental
autoimmune encephalomyelitis. J Immunol. 191:4960–4968. 2013.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Cabarrocas J, Bauer J, Piaggio E, Liblau R
and Lassmann H: Effective and selective immune surveillance of the
brain by MHC class I-restricted cytotoxic T lymphocytes. Eur J
Immunol. 33:1174–1182. 2003. View Article : Google Scholar : PubMed/NCBI
|
4
|
Fischer HG and Reichmann G: Brain
dendritic cells and macrophages/microglia in central nervous system
inflammation. J Immunol. 166:2717–2726. 2001. View Article : Google Scholar : PubMed/NCBI
|
5
|
Li Y, Chu N, Hu A, Gran B, Rostami A and
Zhang GX: Increased IL-23p19 expression in multiple sclerosis
lesions and its induction in microglia. Brain. 130:490–501. 2007.
View Article : Google Scholar
|
6
|
Langrish CL, Chen Y, Blumenschein WM,
Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA and
Cua DJ: IL-23 drives a pathogenic T cell population that induces
autoimmune inflammation. J Exp Med. 201:233–240. 2005. View Article : Google Scholar : PubMed/NCBI
|
7
|
Luchtman DW, Ellwardt E, Larochelle C and
Zipp F: IL-17 and related cytokines involved in the pathology and
immunotherapy of multiple sclerosis: Current and future
developments. Cytokine Growth Factor Rev. 25:403–413. 2014.
View Article : Google Scholar : PubMed/NCBI
|
8
|
McFarland HF and Martin R: Multiple
sclerosis: A complicated picture of autoimmunity. Nat Immunol.
8:913–919. 2007. View
Article : Google Scholar : PubMed/NCBI
|
9
|
Castro-Borrero W, Graves D, Frohman TC,
Flores AB, Hardeman P, Logan D, Orchard M, Greenberg B and Frohman
EM: Current and emerging therapies in multiple sclerosis: A
systematic review. Ther Adv Neurol Disord. 5:205–220. 2012.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Wu B, Liu M and Zhang S: Cochrane
systematic review: danshen agents for acute ischaemic stroke.
Chinese Journal of Evidence-Based Medicine. 2:101–105. 2005.
|
11
|
Cheng TO: Cardiovascular effects of
Danshen. Int J Cardiol. 121:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
12
|
Xu S and Liu P: Tanshinone II-A: New
perspectives for old remedies. Expert Opin Ther Pat. 23:149–153.
2013. View Article : Google Scholar
|
13
|
Ren B, Zhang YX, Zhou HX, Sun FW, Zhang
ZF, Wei Z, Zhang CY and Si DW: Tanshinone IIA prevents the loss of
nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and
iNOS in the MPTP model of Parkinson's disease. J Neurol Sci.
348:142–152. 2015. View Article : Google Scholar
|
14
|
Jiang P, Li C, Xiang Z and Jiao B:
Tanshinone IIA reduces the risk of Alzheimer's disease by
inhibiting iNOS, MMP-2 and NF-κBp65 transcription and translation
in the temporal lobes of rat models of Alzheimer's disease. Mol Med
Rep. 10:689–694. 2014.PubMed/NCBI
|
15
|
Zhang K, Wang J, Jiang H, Xu X, Wang S,
Zhang C, Li Z, Gong X and Lu W: Tanshinone IIA inhibits
lipopolysaccharide-induced MUC1 overexpression in alveolar
epithelial cells. Am J Physiol Cell Physiol. 306:C59–C65. 2014.
View Article : Google Scholar
|
16
|
Zhu W, Lu Q, Chen HW, Feng J, Wan L and
Zhou DX: Protective effect of sodium tanshinone II A sulfonate on
injury of small intestine in rats with sepsis and its mechanism.
Chin J Integr Med. 18:496–501. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Liu M, Yang J and Li M: Tanshinone IIA
attenuates interleukin-17A-induced systemic sclerosis
patient-derived dermal vascular smooth muscle cell activation via
inhibition of the extracellular signal-regulated kinase signaling
pathway. Clinics (Sao Paulo). 70:250–256. 2015. View Article : Google Scholar
|
18
|
Mao YS, Lu CZ, Wang X and Xiao BG:
Induction of experimental autoimmune encephalomyelitis in Lewis
rats by a viral peptide with limited homology to myelin basic
protein. Exp Neurol. 206:231–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Jokubaitis VG, Gresle MM, Kemper DA,
Doherty W, Perreau VM, Cipriani TL, Jonas A, Shaw G, Kuhlmann T,
Kilpatrick TJ and Butzkueven H: Endogenously regulated Dab2 worsens
inflammatory injury in experimental autoimmune encephalomyelitis.
Acta Neuropathol Commun. 1:322013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Nitsch R, Pohl EE, Smorodchenko A,
Infante-Duarte C, Aktas O and Zipp F: Direct impact of T cells on
neurons revealed by two-photon microscopy in living brain tissue. J
Neurosci. 24:2458–2464. 2004. View Article : Google Scholar : PubMed/NCBI
|
21
|
Aktas O, Smorodchenko A, Brocke S,
Infante-Duarte C, Schulze Topphoff U, Vogt J, Prozorovski T, Meier
S, Osmanova V, Pohl E, et al: Neuronal damage in autoimmune
neuroinflammation mediated by the death ligand TRAIL. Neuron.
46:421–432. 2005. View Article : Google Scholar : PubMed/NCBI
|
22
|
del Pilar Martin M, Cravens PD, Winger R,
Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B,
Karandikar NJ, et al: Decrease in the numbers of dendritic cells
and CD4+ T cells in cerebral perivascular spaces due to
natalizumab. Arch Neurol. 65:1596–1603. 2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Babbe H, Roers A, Waisman A, Lassmann H,
Goebels N, Hohlfeld R, Friese M, Schröder R, Deckert M, Schmidt S,
et al: Clonal expansions of CD8 (+) T cells dominate the T cell
infiltrate in active multiple sclerosis lesions as shown by
micro-manipulation and single cell polymerase chain reaction. J Exp
Med. 192:393–404. 2000. View Article : Google Scholar : PubMed/NCBI
|
24
|
Kuhlmann T, Lingfeld G, Bitsch A,
Schuchardt J and Brück W: Acute axonal damage in multiple sclerosis
is most extensive in early disease stages and decreases over time.
Brain. 125:2202–2212. 2002. View Article : Google Scholar : PubMed/NCBI
|
25
|
Meuth SG, Herrmann AM, Simon OJ, Siffrin
V, Melzer N, Bittner S, Meuth P, Langer HF, Hallermann S, Boldakowa
N, et al: Cytotoxic CD8+ T cell-neuron interactions:
Perforin-dependent electrical silencing precedes but is not
causally linked to neuronal cell death. J Neurosci. 29:15397–15409.
2009. View Article : Google Scholar : PubMed/NCBI
|
26
|
Zang YC, Li S, Rivera VM, Hong J, Robinson
RR, Breitbach WT, Killian J and Zhang JZ: Increased CD8+ cytotoxic
T cell responses to myelin basic protein in multiple sclerosis. J
Immunol. 172:5120–5127. 2004. View Article : Google Scholar : PubMed/NCBI
|
27
|
Yu Q, Chen H, Sheng L, Liang Y and Li Q:
Sodium tanshinone IIA sulfonate prolongs the survival of skin
allografts by inhibiting inflammatory cell infiltration and T cell
proliferation. Int Immunopharmacol. 22:277–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Li HZ, Lu YH, Huang GS, Chen Q, Fu Q and
Li ZL: Tanshinone II A inhibits dendritic cell-mediated adaptive
immunity: Potential role in anti-atherosclerotic activity. Chin J
Integr Med. 20:764–769. 2014. View Article : Google Scholar
|
29
|
Nikić I, Merkler D, Sorbara C, Brinkoetter
M, Kreutzfeldt M, Bareyre FM, Brück W, Bishop D, Misgeld T and
Kerschensteiner M: A reversible form of axon damage in experimental
autoimmune encephalomyelitis and multiple sclerosis. Nat Med.
17:495–499. 2011. View
Article : Google Scholar
|
30
|
Pitt D, Werner P and Raine CS: Glutamate
excitotoxicity in a model of multiple sclerosis. Nat Med. 6:67–70.
2000. View Article : Google Scholar
|
31
|
Jack C, Ruffini F, Bar-Or A and Antel JP:
Microglia and multiple sclerosis. J Neurosci Res. 81:363–373. 2005.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Chen TH, Hsu YT, Chen CH, Kao SH and Lee
HM: Tanshinone IIA from Salvia miltiorrhiza induces heme
oxygenase-1 expression and inhibits lipopolysaccharide-induced
nitric oxide expression in RAW 264.7 cells. Mitochondrion.
7:101–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
33
|
Choi HS, Cho DI, Choi HK, Im SY, Ryu SY
and Kim KM: Molecular mechanisms of inhibitory activities of
tanshinones on lipopolysaccharide-induced nitric oxide generation
in RAW 264.7 cells. Arch Pharm Res. 27:1233–1237. 2004. View Article : Google Scholar
|
34
|
Fan GW, Gao XM, Wang H, Zhu Y, Zhang J, Hu
LM, Su YF, Kang LY and Zhang BL: The anti-inflammatory activities
of Tanshinone IIA, an active component of TCM, are mediated by
estrogen receptor activation and inhibition of iNOS. J Steroid
Biochem Mol Biol. 113:275–280. 2009. View Article : Google Scholar : PubMed/NCBI
|
35
|
Cao FL, Xu M, Wang Y, Gong KR and Zhang
JT: Tanshinone IIA attenuates neuropathic pain via inhibiting glial
activation and immune response. Pharmacol Biochem Behav. 128:1–7.
2015. View Article : Google Scholar
|
36
|
Huitinga I, van Rooijen N, de Groot CJ,
Uitdehaag BM and Dijkstra CD: Suppression of experimental allergic
encephalo-myelitis in Lewis rats after elimination of macrophages.
J Exp Med. 172:1025–1033. 1990. View Article : Google Scholar : PubMed/NCBI
|
37
|
Heppner FL, Greter M, Marino D, Falsig J,
Raivich G, Hövelmeyer N, Waisman A, Rülicke T, Prinz M, Priller J,
et al: Experimental autoimmune encephalomyelitis repressed by
microglial paralysis. Nat Med. 11:146–152. 2005. View Article : Google Scholar : PubMed/NCBI
|
38
|
Bullard DC, Hu X, Schoeb TR, Axtell RC,
Raman C and Barnum SR: Critical requirement of CD11b (Mac-1) on T
cells and accessory cells for development of experimental
autoimmune encephalomyelitis. J Immunol. 175:6327–6333. 2005.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Qin S, Wen J, Bai XC, Chen TY, Zheng RC,
Zhou GB, Ma J, Feng JY, Zhong BL and Li YM: Endogenous n-3
polyunsaturated fatty acids protect against imiquimod-induced
psoriasis-like inflammation via the IL-17/IL-23 axis. Mol Med Rep.
9:2097–2104. 2014.PubMed/NCBI
|
40
|
Ghadimi D, Helwig U, Schrezenmeir J,
Heller KJ and de Vrese M: Epigenetic imprinting by commensal
probiotics inhibits the IL-23/IL-17 axis in an in vitro model of
the intestinal mucosal immune system. J Leukoc Biol. 92:895–911.
2012. View Article : Google Scholar : PubMed/NCBI
|
41
|
Gaffen SL, Jain R, Garg AV and Cua DJ: The
IL-23-IL-17 immune axis: From mechanisms to therapeutic testing.
Nat Rev Immunol. 14:585–600. 2014. View Article : Google Scholar : PubMed/NCBI
|
42
|
Cua DJ, Sherlock J, Chen Y, Murphy CA,
Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, et al:
Interleukin-23 rather than interleukin-12 is the critical cytokine
for autoimmune inflammation of the brain. Nature. 421:744–748.
2003. View Article : Google Scholar : PubMed/NCBI
|
43
|
McGeachy MJ, Chen Y, Tato CM, Laurence A,
Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O'Shea JJ and Cua
DJ: The interleukin 23 receptor is essential for the terminal
differentiation of interleukin 17-producing effector T helper cells
in vivo. Nat Immunol. 10:314–324. 2009. View Article : Google Scholar : PubMed/NCBI
|
44
|
Gyuelveszi G, Haak S and Becher B:
IL-23-driven encephalo-tropism and Th17 pola rization during
CNS-inflammation in vivo. Eur J Immunol. 39:1864–1869. 2009.
View Article : Google Scholar
|
45
|
Ghoreschi K, Laurence A, Yang XP, Tato CM,
McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N,
et al: Generation of pathogenic T (H) 17 cells in the absence of
TGF-β signalling. Nature. 467:967–971. 2010. View Article : Google Scholar : PubMed/NCBI
|
46
|
Goverman J: Autoimmune T cell responses in
the central nervous system. Nat Rev Immunol. 9:393–407. 2009.
View Article : Google Scholar : PubMed/NCBI
|
47
|
Kebir H, Kreymborg K, Ifergan I,
Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N,
Becher B and Prat A: Human TH17 lymphocytes promote blood-brain
barrier disruption and central nervous system inflammation. Nat
Med. 13:1173–1175. 2007. View
Article : Google Scholar : PubMed/NCBI
|
48
|
Chen Y, Langrish CL, McKenzie B,
Joyce-Shaikh B, Stumhofer JS, McClanahan T, Blumenschein W,
Churakovsa T, Low J, Presta L, et al: Anti-IL-23 therapy inhibits
multiple inflammatory pathways and ameliorates autoimmune
encepha-lomyelitis. J Clin Invest. 116:1317–1326. 2006. View Article : Google Scholar : PubMed/NCBI
|
49
|
Tzartos JS, Friese MA, Craner MJ, Palace
J, Newcombe J, Esiri MM and Fugger L: Interleukin-17 production in
central nervous system-infiltrating T cells and glial cells is
associated with active disease in multiple sclerosis. Am J Pathol.
172:146–155. 2008. View Article : Google Scholar :
|
50
|
Komiyama Y, Nakae S, Matsuki T, Nambu A,
Ishigame H, Kakuta S, Sudo K and Iwakura Y: IL-17 plays an
important role in the development of experimental autoimmune
encephalomy-elitis. J Immunol. 177:566–573. 2006. View Article : Google Scholar : PubMed/NCBI
|
51
|
Kawanokuchi J, Shimizu K, Nitta A, Yamada
K, Mizuno T, Takeuchi H and Suzumura A: Production and functions of
IL-17 in microglia. J Neuroimmunol. 194:54–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
52
|
Trajkovic V, Stosic-Grujicic S, Samardzic
T, Markovic M, Miljkovic D, Ramic Z and Mostarica Stojkovic M:
Interleukin-17 stimulates inducible nitric oxide synthase
activation in rodent astrocytes. J Neuroimmunol. 119:183–191. 2001.
View Article : Google Scholar : PubMed/NCBI
|
53
|
Wojkowska DW, Szpakowski P,
Ksiazek-Winiarek D, Leszczynski M and Glabinski A: Interactions
between neutrophils, Th17 cells and chemokines during the
initiation of experimental model of multiple sclerosis. Mediators
Inflamm. 2014:5904092014. View Article : Google Scholar
|
54
|
Paintlia MK, Paintlia AS, Singh AK and
Singh I: Synergistic activity of interleukin-17 and tumor necrosis
factor-α enhances oxidative stress-mediated oligodendrocyte
apoptosis. J Neurochem. 116:508–521. 2011. View Article : Google Scholar :
|
55
|
Prineas JW, Barnard RO, Kwon EE, Sharer LR
and Cho ES: Multiple sclerosis: Remyelination of nascent lesions.
Ann Neurol. 33:137–151. 1993. View Article : Google Scholar : PubMed/NCBI
|
56
|
Miossec P and Kolls JK: Targeting IL-17and
TH17 cells in chronic inflammation. Nat Rev Drug Disco. 11:763–776.
2012. View Article : Google Scholar
|